波士顿科学创新研发的AGENT DCB球囊导管获批

美通社05-24

(医药健闻2024年5月24日讯)波士顿科学旗下AGENT紫杉醇涂层PTCA球囊导管（DCB）（AGENT DCB）获得国家药品监督管理局（NMPA）批准，用于冠状动脉支架内再狭窄（ISR）的治疗。支架内再狭窄是指在原植入支架内再次发生直径狭窄程度＞50%的病变。作为全球首款获得美国FDA批准上市的冠脉DCB产品，AGENT DCB是目前唯一同时获得欧盟CE、FDA及NMPA批准的冠脉DCB产品，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2437033470?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-05-24 19:27","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2437033470","market":"us","top_or_hot":-1,"title":"波士顿科学创新研发的AGENT DCB球囊导管获批","media":"美通社","content":"<div>\n<p>(医药健闻2024年5月24日讯)波士顿科学旗下AGENT紫杉醇涂层PTCA球囊导管（DCB）（AGENT DCB）获得国家药品监督管理局（NMPA）批准，用于冠状动脉支架内再狭窄（ISR）的治疗。支架内再狭窄是指在原植入支架内再次发生直径狭窄程度＞50%的病变。作为全球首款获得美国FDA批准上市的冠脉DCB产品，AGENT DCB是目前唯一同时获得欧盟CE、FDA及NMPA批准的冠脉DCB产品，...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2024-05-24/doc-inawisip6709523.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>波士顿科学创新研发的AGENT DCB球囊导管获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n波士顿科学创新研发的AGENT DCB球囊导管获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-24 19:27 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2024-05-24/doc-inawisip6709523.shtml><strong>美通社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(医药健闻2024年5月24日讯)波士顿科学旗下AGENT紫杉醇涂层PTCA球囊导管（DCB）（AGENT DCB）获得国家药品监督管理局（NMPA）批准，用于冠状动脉支架内再狭窄（ISR）的治疗。支架内再狭窄是指在原植入支架内再次发生直径狭窄程度＞50%的病变。作为全球首款获得美国FDA批准上市的冠脉DCB产品，AGENT DCB是目前唯一同时获得欧盟CE、FDA及NMPA批准的冠脉DCB产品，...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2024-05-24/doc-inawisip6709523.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1718418525.SGD","symbol_name":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-05-24/doc-inawisip6709523.shtml","article_id":"2437033470","we_media_id":null,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/usstock/c/2024-05-24/doc-inawisip6709523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2437033470","pubTimestamp":1716550020,"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"波士顿科学旗下AGENT紫杉醇涂层PTCA球囊导管获得国家药品监督管理局批准，用于冠状动脉支架内再狭窄的治疗。作为全球首款获得美国FDA批准上市的冠脉DCB产品，AGENT DCB是目前唯一同时获得欧盟CE、FDA及NMPA批准的冠脉DCB产品，将为中国冠脉介入治疗带来更多元的选择。此次最新获批的AGENTDCB专为抵达并穿过远端复杂病变而进行了创新设计构造。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","BK4581":"高盛持仓","BK4504":"桥水持仓","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","BK4585":"ETF&股票定投概念","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","BK4082":"医疗保健设备","LU0882574055.USD":"富达全球健康医疗A ACC","BK4588":"碎股","LU0122379950.USD":"贝莱德世界健康科学A2","BSX":"波士顿科学"},"translate_title":"AGENT DCB balloon catheter developed by Boston Scientific Innovation was approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1},"content_text":"(医药健闻2024年5月24日讯)波士顿科学旗下AGENT紫杉醇涂层PTCA球囊导管（DCB）（AGENT DCB）获得国家药品监督管理局（NMPA）批准，用于冠状动脉支架内再狭窄（ISR）的治疗。支架内再狭窄是指在原植入支架内再次发生直径狭窄程度＞50%的病变。作为全球首款获得美国FDA批准上市的冠脉DCB产品，AGENT DCB是目前唯一同时获得欧盟CE、FDA及NMPA批准的冠脉DCB产品，将为中国冠脉介入治疗带来更多元的选择。    药物涂层球囊不会在人体中遗留永久置入物，被认为是PCI的另一种治疗策略。药物涂层球囊表面覆盖了一层抗增殖药物，其药物成分能在单次球囊扩张的时间内迅速渗透进血管壁，发挥抑制平滑肌细胞增殖与迁移的作用，从而阻碍再狭窄进程。在美国，10%的PCI术后仍会出现ISR问题，使用DCB可将治疗剂量的药物转移到血管壁，帮助防止ISR再次发生。目前，DCB已被证实可以应对ISR及冠状动脉小血管原发病变（SVD）。作为全球微创介入医疗器械的创新引领者，波士顿科学在冠脉介入治疗领域拥有深厚的技术积累和多元的产品组合。此前，波士顿科学旗下多款PCI解决方案已在中国临床广泛应用，涵盖PCI诊疗的全流程。此次最新获批的AGENTDCB专为抵达并穿过远端复杂病变而进行了创新设计构造。在一项600例患者入组的多中心、前瞻性、随机对照AGENTIDE研究中，结果显示，AGENTDCB组在术后12个月的靶病变失败率低于无涂层球囊血管成形术组（17.9%vs.28.6%，P=0.003）。到目前为止，全球已有超过10万名患者在临床试验和商业环境中接受过AGENTDCB治疗，随着该产品正式在华落地，将进一步丰富波士顿科学的冠脉介入产品组合，服务广大冠心病患者的健康需求。\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2437033470"}